X
Xilio Therapeutics, Inc. (XLO)
NCM – Real Time Price. Currency in USD
7.79
+0.06 (0.78%)
Market open: May 13, 2026, 12:01 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
7.79
+0.06 (0.78%)
Market open: May 13, 2026, 12:01 PM EDT
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company’s pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
| Name | Position |
|---|---|
| Dr. Katarina Luptakova M.D. | Chief Medical Officer |
| Dr. Rene Russo BCPS, Pharm.D. | President, CEO & Director |
| Dr. Scott Coleman Ph.D. | Chief Development Officer |
| Dr. Uli Bialucha Ph.D. | Chief Scientific Officer |
| Mr. Christopher Frankenfield | CFO & COO |
| Mr. Kevin M. Brennan | Senior Vice President of Finance & Accounting |
| Mr. Nathan McBride | Chief Information Officer |
| Ms. Caroline Hensley | Chief Legal Officer |
| Ms. Ruth du Moulin | Senior Vice President of Medical Affairs |
| Date | Type | Document |
|---|---|---|
| 2026-05-12 | S-3 | xlo-20260512.htm |
| 2026-04-28 | ARS | 2026_04_28_-_ars.pdf |
| 2026-04-16 | 8-K | xlo-20260416.htm |
| 2026-03-23 | S-8 | xlo-20260323.htm |
| 2026-03-23 | 8-K | xlo-20260323.htm |
| 2026-03-12 | 8-K | xlo-20260312.htm |
| 2026-03-09 | 8-K | xlo-20260309.htm |
| 2026-02-24 | 8-K | xlo-20260223.htm |
| 2026-02-12 | 8-K | d85184d8k.htm |
| 2026-01-26 | DEF 14A | xlo-20260122.htm |